TAGS: Northampton Saints LATEST RUGBY WORLD MAGAZINE SUBSCRIPTION DEALS Northampton Saints today announced that Keith Barwell will be standing down as the club’s chairman in September 2011.Mr Barwell has been synonymous with the Saints for over 20 years. One of the club’s first box holders in the late-1980s, his initial million-pound investment in 1995 ensured that the Saints made the transition to professional rugby union successfully and Mr Barwell has remained one of the driving forces within the English club game ever since.During Mr Barwell’s time as chairman the Saints won the Heineken Cup, European Challenge Cup and LV= Cup, provided the coach for the successful British and Irish Lions tour to South Africa in 1997 as well as numerous players for several international teams as well as the Lions.Off the field Franklin’s Gardens was turned into the pre-eminent dedicated rugby facility in Europe. The stadium was completely rebuilt between 2001 and 2002, with a further extension in 2005, and in the last 18 months Mr Barwell has worked tirelessly to ensure that the arena will be completed with a new North Stand.With Mr Barwell at the helm the Saints has also demonstrated that it is possible for a rugby club to also succeed as a viable business. After an initial public offering in 2001, Northampton Saints plc has continued to run at a surplus in every subsequent year, the only club in England to do so.In 2009 Mr Barwell was honoured with an OBE for services to Northampton.“I have had the fortune of being involved in club rugby during a very exciting time and it has been an honour being chairman of the Saints,” Mr Barwell said. “I have worked with a superb board of directors and some excellent directors of rugby and coaches. It has been a roller-coaster ride, with both silverware and relegation, and every minute of it will live long in the memory.“Although I have been chairman, I am first and foremost a Saints fan and have had the privilege of watching some world class players wear the black, green and gold. It has also been an honour to serve the Saints fans, who put in considerable amounts of time and money supporting the club, and we have had an excellent relationship, as I have had with the staff at the club.“I believe that it is the right time for me to be stepping aside as chairman. The club is on an upward trend on and off the field and will be in safe hands going forward.” Although he is standing down as chairman, Mr Barwell will continue on the club’s board of directors for a further 12 months with the Barwell family remaining as majority shareholders.Mr Barwell’s son, Leon, will take over as chairman in September, following a unanimous vote of the Northampton Saints board in early March. A director of The Barwell Corporation and VSG, a nationwide security company, Leon Barwell has been on the Saints’ board since 1999 and has been involved in a wide range of projects, including the initial public offering and formation of Northampton Saints plc and the redevelopment of Franklin’s Gardens.“It’s a huge honour for me to be able to play such an active role in a club that means so much to me,” said Leon Barwell. “As a family we’re very proud of what’s been achieved at the Saints over the past 15 years, and one thing you know for sure is that we have to go as far again in the next 15 if we want to stay at the top of the game.“I feel very lucky to be coming into the role with a very strong board around me, a very good executive management team on and off the field and the best supporters in the country. I’m certainly looking forward to working with all of them, especially Tony Hewitt as vice-chairman, and with the current squad of players we’ve got and the players that are joining us I’m looking forward to leading the club to consistent levels of success through the coming years. Throughout the club there is that burning ambition which is a great driver for us.“Keith is obviously a hard act to follow, not just within the environment in Northampton but the impact and presence he has on the national scene. He has put Northampton well and truly on the international sporting map. But I am no less passionate or determined than he is and it’s a challenge I’m relishing.”Saints chief executive Allan Robson also paid tribute to Mr Barwell.“Keith will live on forever in the history of the Saints, and deservedly so,” he said. “The club would not be where it is without his time, effort and commitment. He has constantly striven for success both on and off the field, and has shown that you can achieve both in professional club rugby. “As one of the original chairmen whose money helped club rugby turn professional in the first place, Keith has also been one of the driving forces behind the development of the club game as whole and Premiership Rugby will not be the same without him.”In addition to Leon Barwell taking over as chairman, September 2011 will also see the appointment of Tony Hewitt in the brand new role of vice-chairman. Mr Hewitt has been on Saints’ board of directors since 1995 and played a leading role in the redevelopment of Franklin’s Gardens as well as the share offer for Northampton Saints plc.
Mun Jeong Heon / A.M ArchitectsSave this projectSaveMun Jeong Heon / A.M Architects ArchDaily Houses “COPY” Photographs: Kim Jae-kyeongText description provided by the architects. The concept of Architecture like Promenade, which accumulates spacial experience, well expressed in piled walls with sequential view of interior and exterior, which servers as an element to add sense of depth and the direction of entry. The controlled form of the entrance placed in the entry part is an objet for moving toward another space. On going into the entry space, the house, surrounded by horizontal free-standing walls floating in the air, appears overlapped. Free-standing walls of exposed concrete to emphasize horizontal stream are used as a method to attract people’s eyes and become visually magnified.Save this picture!© Kim Jae KyeongThe light of nature falling long in dynamic angles through the cantilever decoration beam protruded from the flat surface of the wall, the light of nature falling is naturally ushered to the deck in front of the entrance with the property of concrete, and makes the place of main entrance recognized with free-standing walls. Also, the glance extending long along the stream of free-standing wall stays a little far in the foot of the mountain passing over spindle tree fence. Enter the inside, over the transparent window, we can see a tree in the back yard along the grass extending the floor all in one, which is the architectural element to induce boundless horizontal extension of the space visually. Save this picture!© Kim Jae Kyeong As soon as we go into the living room along the corridor, we can feel the energy of the extended light going down softly through the ceiling. The composition of walls repeating solid and void serves as an element of architectural promenaded which makes us feel the outside and inside space sequentially with the natural light, and guides the direction of entry with tension.Free-Standing Walls for Selective View The inner garden seen from the livingroom expressing the changing seasons with free-standing walls for selective view keeps an indirect eye on the landscape of distant mountain hanged at the end of exposed concrete free-standing walls through toenmaru connected visually with the study. Such architectural element becomes a device to draw nature selectively, and to makes a metaphoric communication between interior space and exterior space possible.Save this picture!© Kim Jae KyeongThe domain created through a layer and a layer communicates with nature along with various forms of walls controlling the visual and spatial movements. Organic setting up of interior and exterior spaces connecting to corridor, back yard, living room, inner garden, study and toenmaru creates the architecture of incessant relationship and stream.Save this picture!Floor PlanProject gallerySee allShow lessPresido Trust Rejects Shortlisted Proposals, Calls Off CompetitionArchitecture NewsTourist Centre on Klekovaca Mountain International CompetitionArticles Share South Korea ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/473526/mun-jeong-heon-a-m-architects Clipboard Save this picture!© Kim Jae Kyeong+ 15 Share “COPY” Mun Jeong Heon / A.M Architects Architects: A.M Architects Area Area of this architecture project Projects Area: 99 m² Area: 99 m² Photographs ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/473526/mun-jeong-heon-a-m-architects Clipboard CopyAbout this officeA.M ArchitectsOfficeFollowProductsWoodConcrete#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesGimcheon-siHousesWoodSouth KoreaPublished on February 05, 2014Cite: “Mun Jeong Heon / A.M Architects” 05 Feb 2014. ArchDaily. Accessed 11 Jun 2021.
LeiLani DowellMeeting at Riverside Church on May 10, anti-war activists from the New York metropolitan area gave a kick-start to three weeks of activities in solidarity with the anti-fascist movement in Eastern Ukraine and opposing new U.S.-NATO aggression against Russia.Former WBAI Program Director Bernard White introduced the organizers’ goal: to infuse the anti-war movement with the facts and arguments about Ukraine that counter the ocean of lies in the corporate media. Organizers will reach out with this knowledge to ever-broader sectors of the population. White is now with Community Progressive Radio (cprmetro.org).Most of the room’s 140 seats were occupied. The International Action Center call mobilized a broad section of veteran and newer anti-imperialist and anti-racist activists who know how to reach out with the truth — and with the movement’s call for actions from May 9 to May 26.The day’s many speakers honed their comments to tight time frames, offering a condensed dose of information and analysis, all recorded by CPR Metro and videotaped by five videographers for use around the world.Glenn FordJudging from the enthusiastic reaction, this group of activists — and others around the country — will be organizing, leafleting and using social media to motivate more and more of an already anti-war population into active resistance. The main lesson: The people must oppose the U.S. and EU, which have imposed a pro-austerity, neoliberal regime on Ukraine that depends on fascist gangs to stay in power.The IAC’s Sara Flounders; Joe Lombardo, of the United National Antiwar Coalition; IAC co-chair LeiLani Dowell; and others urged anti-war action in the streets. As Lombardo said, “Demonstrations are even better than meetings” for outreach to the people.There were anger-raising descriptions of murderous fascist attacks on progressive activists in Odessa, described by Workers World contributing editor Greg Butterfield, and in Mariupol, described by Bill Dores, of the International League of People’s Struggle.‘First armed resistance to austerity’ in EuropeSara FloundersBut this was balanced by the recognition, as Flounders said, that “the uprising in Ukraine’s East is the first armed resistance to austerity,” which the EU and U.S. banks are imposing throughout Europe on the working class. Ukraine’s workers are setting an example for Europe.Dustin Ponder, of the Freedom Road Socialist Organization, detailed what International Monetary Fund — and EU-imposed cutbacks would mean for Ukraine’s workers.Glenn Ford, of Black Agenda Report, characterized U.S. intervention in Ukraine as another setback for U.S. imperialism. President Barack “Obama’s attempt to destabilize Russia … is a symptom of desperation … and will weaken the grip of U.S. imperialism on the world” just as George W. Bush’s invasion of Iraq in 2003 did, Ford asserted.Joe LombardoFormer CIA analyst Ray McGovern, now an anti-war activist, gave historical background. He described the agreement between USSR President Mikhail Gorbachev and U.S. Secretary of State James Baker in 1990, when the USSR withdrew 300,000 troops from the German Democratic Republic. There was a handshake that NATO would not move an inch eastward.Instead NATO has moved to Russia’s borders. However, the Russian government drew a red line in 2008 when it said it would refuse to accept NATO in Georgia and Ukraine, and according to McGovern, the Russians mean it.Larry Holmes, of the Peoples Power Assembly, contributed a unifying concept. Through the class struggle he linked the upcoming and unprecedented worldwide day of action by low-wage workers — May 15 — with the anti-war movement.Holmes noted that about half of the 50 McDonald’s operating in the Ukraine were now closed — those in the East. The majority of those still open are in the capital, Kiev, where the coup government holds power.The anti-imperialist analysis wasn’t limited to Ukraine, but included exposure of U.S. imperialism’s intervention against Venezuela, with comments from William Camacaro, of the Alberto Lovera Bolivarian Circle; against the people of the Philippines by Bernadette Ellorin, of BAYAN USA; and against the Syrian people by Avin Dirki, of the Syrian American Forum.Former U.S. Attorney General Ramsey Clark sent a message of solidarity. The organizers showed a PowerPoint slideshow with background on Ukraine, which is available at no2nato.org.In New York, the demonstration will be on Memorial Day, May 26, at 1 p.m. in Times Square. For more information about other demonstrations, see iacenter.org or unacpeace.org.WW photos: G. DunkelFacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
Editorial del 2 de enero de 2019 – Es una isla a solo 90 millas de los Estados Unidos que ha sido invadida, bloqueada y que aún está parcialmente ocupada en la Bahía de Guantánamo por el más poderoso de todos los países imperialistas.Sin embargo, desde hace 60 años, Cuba revolucionaria ha sobrevivido como un país dedicado a construir el socialismo en el país, al mismo tiempo que ayuda a los movimientos de liberación y los pueblos oprimidos en otros países.Cuba no solo ha sobrevivido. Ha inspirado a millones de personas en América Latina, África y en todo el mundo con su aplicación ingeniosa de la teoría y la práctica revolucionaria a los problemas impuestos por las amenazas imperialistas y el subdesarrollo.La clave de la fuerza del movimiento revolucionario que el 1 de enero de 1959 expulsó a la dictadura de Batista, esa notoria pandilla de torturadores y explotadores que había hecho de Cuba un paraíso para los millonarios estadounidenses y un infierno para campesinas/os y trabajadoras/es, fue que destruyó el viejo estado represivo y estableció estructuras para garantizar el gobierno de las/os trabajadores y agricultores.Casi de inmediato, la revolución lanzó un programa de alfabetización, enviando a estudiantes de secundaria al campo para enseñar a las/os pobres de las zonas rurales cómo leer y escribir. Pronto les proporcionó materiales para construir casas reales, con agua corriente y luz eléctrica. Los cortadores de caña de azúcar se regocijaron mientras quemaban las chozas con suelo de tierra y techo de paja de los viejos tiempos.Mujeres y hombres, blancos y negros, se unieron a la milicia popular recientemente organizada para defender su revolución contra los yanquis y sus mercenarios. Una industria cinematográfica revolucionaria describió con sinceridad estos momentos emocionales, y no tuvo miedo de mostrar un atraso que había que superar, como aquellos que todavía abrigaban actitudes sexistas que abucheaban a las milicias femeninas cuando desfilaban. Fue el comienzo del trabajo de concientización del Partido Comunista de Cuba sobre temas de sexo y género.Cuando una invasión contrarrevolucionaria de mercenarios entrenados y financiados por los Estados Unidos llegó en abril de 1961 en Playa Girón, fue derrotada en pocos días con un pueblo armado movilizado junto al ejército regular. En medio de esa invasión, Fidel Castro, el líder inmortal de la revolución, dijo por primera vez al pueblo que Cuba había hecho una “revolución socialista” bajo las narices de los imperialistas yanquis.El hecho mismo de que Fidel llamara socialista a la revolución en medio de la invasión era una prueba de que el socialismo era lo que el pueblo cubano quería y por lo que estaba dispuesto a morir. (Este escritor estaba en la abarrotada oficina de Nueva York del Movimiento 26 de Julio cuando el discurso de Fidel llegó a través de la radio de onda corta. Sus palabras provocaron un estallido de vítores y boinas lanzadas alegremente en el aire).Cuba capturó 1,200 gusanos (contrarrevolucionarios) durante la invasión y obligó al gobierno de los Estados Unidos a pagar reparaciones a cambio de su liberación. Apenas dos semanas después de la invasión, Fidel habló en una gran concentración del Primero de Mayo. Sus palabras capturaron el orgullo y la alegría de las masas cubanas en su gran victoria sobre el imperialismo y sus lacayos:“Y este 1º de Mayo dice mucho de lo que ha sido hasta aquí la Revolución, de lo que ha logrado hasta hoy la Revolución… En este 1º de Mayo, tan distinto de aquellos primeros de mayo, tan distinto sobre todo porque antes aquella fecha era la ocasión en que cada sector obrero expresaba sus demandas, sus ansias de mejoramiento frente a quienes eran sordos por completo a los intereses de su clase, frente a los que no podían ni siquiera responder ni acceder a ninguna de aquellas demandas fundamentales, porque no gobernaban para el pueblo, no gobernaban para los obreros, no gobernaban para los campesinos, no gobernaban para los sectores humildes del país; gobernaban solo para los privilegiados, gobernaban solo para los intereses económicos dominantes. …. ya los obreros saben que todo lo que la Revolución hace, todo lo que el Gobierno hace o pueda hacer, tiene un solo y exclusivo propósito, y es ayudar a su clase, ayudar a su pueblo”.Y la revolución continúa – ¡Viva la revolución cubana, socialista!FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
SHARE Holland was quick to point out that fungicides are not a cure for drought stress, but they do help corn handle environmental stresses like drought better, “It is just another tool in the toolbox and does not replace the need for a good rain and the right time.” She told HAT that growers who used fungicides saw better corn yields because of improved photosynthesis during last year’s drought, “We worked with a grower in northern Illinois who applied Headline to his corn at the beginning of the drought, and we really saw a difference.” She said the corn that was treated had increased green leaf tissue, “He was able to preserve the green leaf tissue on the plant longer and, as a result, was able to provide more energy to the plant with increased photosynthesis.” The grower had higher yields on the crops treated with the fungicide vs. the other areas that were not treated. Those other areas had almost no yield at all because of the drought. Fungicide Use Can Prevent Drought Stress Previous articlePurdue Ag Economist Offers Comparisons Of Crop InsuranceNext articleSeed Consultant 3/13/2013 Closing Comment with Gary Wilhemy Gary Truitt Facebook Twitter Facebook Twitter Dr. Jennifer HollandFungicide use by Indiana farmers is a growing trend, and one that involves some controversy. Critics say the benefits are not worth the investment, but supporters says the benefits go far beyond just disease control. Dr. Jennifer Holland, Technical Market Specialist, Fungicides with BASF, says research shows that photosynthesis is increased with the use of fungicides, “We have research that shows that Headline fungicide increases photo synthesis in corn when applied at V6, and we have seen an even greater impact with our new fungicide Priaxor.” She added BASF testing has found benefits to fungicides far beyond just disease control, most notably an increase in photosynthesis activity in plants. Dr. Holland supports marketing and field sales efforts through research collaboration for BASF Plant Health products, as well as technical positioning, training, and product-use recommendations for the fungicide portfolio. Prior to her current role, Dr. Holland was a member of the BASF Professional Development Program, where she supported the technical team on BASF Plant Health initiatives. Dr. Holland received her bachelor’s degree in genetics from the University of Wisconsin and her doctorate in biology from the University of Missouri. Dr. Holland was raised in Indiana. Home Indiana Agriculture News Fungicide Use Can Prevent Drought Stress Fungicide Use Can Prevent Drought Stress SHARE By Gary Truitt – Mar 12, 2013
News Yemeni journalist killed, nine wounded in Aden airport explosions YemenMiddle East – North Africa Follow the news on Yemen February 26, 2021 Find out more January 6, 2021 Find out more United Nations: press freedom situation “deeply worrying” in Yemen, according to RSF April 1, 2008 – Updated on January 20, 2016 Blog platform Maktoob again accessible RSF_en Receive email alerts to go further Organisation February 11, 2021 Find out more News News News Fixer for foreign reporters held in Aden for past five months YemenMiddle East – North Africa Help by sharing this information The blog platform Maktoob has been accessible again in Yemen since 31 March. The 2,000 Yemeni blogs hosted on this platform could not be updated for about week, without any explanation being given by the authorities or ISPs. Created in 2000, Maktoob is the Internet’s largest English-Arabic platform with more than 4 million users worldwide.——————26.03 – Access to leading Yemeni blog platform has been blocked for several days Reporters Without Borders condemns the fact that access to Maktoobblog.com, a blog platform that hosts more than 2,000 Yemeni blogs, has been blocked for several days without any explanation being given by the country’s ISPs or the platform itself.“The situation of the Internet in Yemen continues to get worse,” the press freedom organisation said. “Without access to Maktoob, Internet users cannot post entries on their blogs and report news. President Ali Abdallah Saleh’s government is having a difficult time with a wave of social unrest throughout the country. We fear the authorities are adopting online censorship measures in a bid to silence these protests.”The information ministry denies blocking the site. But OpenNet Initiative, a partnership of academic institutions in Britain, Canada and the United States, has established that Maktoob continues to be inaccessible for the clients of the state ISP Yemennet. When reached by Reporters Without Borders, Yemennet refused to make any comment.The website of the Yemeni Socialist Party, http://www.aleshteraki.net, has been inaccessible since 12 March without any explanation being offered by the authorities. The YemenPortal news website, http://www.yemenportal.net, is also inaccessible .Reporters Without Borders wrote to the information minister on 12 February requesting an explanation for the government’s Internet filtering policies. He did not reply. Internet users launched a campaign for the unblocking of Yemeni opposition websites on 15 February.On 12 March Reporters Without Borders released a list of “countries under surveillance” because of their Internet policies. Yemen is on the list.
News RSF laureates support jailed Vietnamese journalist Pham Doan Trang Help by sharing this information Three more independent reporters arrested in Vietnam VietnamAsia – Pacific Reporters Without Borders condemns journalist Nguyen Van Khuong’s arrest yesterday in Ho Chi Minh City in connection with his undercover investigative reporting for the newspaper Tuoi Tre. Khuong, who writes under the pen-name of Hoang Khuong, is to be held for four months while the authorities investigate his use of a bribe to expose traffic police corruption.“Khuong should not be charged with bribery because of what he did in the course of an undercover investigation,” Reporters Without Borders said. “He was acting as a reporter, not for personal gain. He is a well-known journalist who has written many stories about police corruption. The authorities should free him at once and abandon any thought of prosecuting him in connection with what he exposed. On the contrary, they should take the appropriate action in response to his investigative reporting, which was in the public interest.”Police searched Khuong’s home and office when arresting him yesterday in connection with his research for an article in which, to obtain irrefutable evidence, he adopted a traffic offender’s identity and, using an intermediary, paid a bribe of 15 million dong (715 dollars) to a police officer, Huynh Minh Duc, to obtain the release of an impounded vehicle. Duc was arrested after Khuong’s story was published. The police nonetheless successfully pressured Khuong’s newspaper into suspending him on 3 December.Khuong’s stories about police officers who take bribes to turn a blind eye to traffic violations have made him famous and have prompted angry criticism of the police by the public. Receive email alerts RSF_en to go further VietnamAsia – Pacific April 7, 2021 Find out more News April 27, 2021 Find out more News January 3, 2012 – Updated on January 20, 2016 Newspaper reporter arrested for undercover investigation of police corruption Vietnam sentences journalist Tran Thi Tuyet Dieu to eight years in prison April 22, 2021 Find out more Follow the news on Vietnam News Organisation
WhatsApp Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS By Digital AIM Web Support – February 4, 2021 434.0 Reported Product RevenueJPY (billion) -1.5% FY2020 GUIDANCE Full-Year Management Guidance Confirmed; Reported EPS Upgrade on More Favorable Tax Rate Assumption and Increased Forecast for Free Cash Flow Reflecting Additional Sale of Securities OSAKA, Japan–(BUSINESS WIRE)–Feb 4, 2021– Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK ) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFFICER COSTA SAROUKOS commented: “Our third-quarter results demonstrate the resilience of our business model and the depth of our portfolio, with strong growth generated by our 14 global brands. As a values-based and R&D driven biopharmaceutical company, we remain focused on bringing life-transforming treatments to people with high unmet needs around the world. With the first of our seven potential filings in the next 12 months complete, we look forward to delivering the next generation of potentially transformative medicines and maintaining our commitment to patients, our people and the planet. “While maintaining business momentum, we also continue to deliver on our financial commitments, realizing strong year-to-date margins and cash flow, and exceeding our target for non-core asset divestitures. This progress reflects our ability to effectively and efficiently integrate the operations of Takeda and Shire, as we capture synergies and focus investment in our key business areas. “Takeda’s strong financial performance in Q3 allows us to confirm management guidance for FY2020, with further growth acceleration expected in Q4 as we conclude the fiscal year. Reflecting on the transformation of Takeda over the past few years and the world-class R&D engine we have built, we look to 2021 as an important inflection point, filled with a number of pivotal milestones that will position us for long-term sustainable growth.” FINANCIAL AND BUSINESS HIGHLIGHTS Results for Q3 FY2020 YTD (Nine-Month Period Ended December 31, 2020) 178.9 319.3 +20.4% 6.5 Q3 FY2020 YTD vs. PRIOR YEAR Operating Profit Oncology Press Release 2,427.5 180.5 Low-single-digit growth Revenue FY2020 PRIOR FORECAST (October 2020) Immunoglobulin 2,427.5 vs. PRIOR YEAR WhatsApp 750-850 +29.2% +4.5% +24.0% +8.3pp 32.2% High-single-digit growth 116 984.0 Free Cash Flow (Non-IFRS) (1) (4) World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19 -3.8% 434.0 14.8% Revenue TAKHZYRO Local NewsBusiness -7.2% Twitter Net Profit 610.0 CORE (Non-IFRS) (1) Takeda initiates a clinical phase 1/2 study in Japan of TAK-919, Moderna’s COVID-19 vaccine candidate 30.8% UnderlyingManagement Guidance 984.0 3,200.0 Product 124.0 (1)Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2)Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3)Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs. (4)Free Cash Flow represents cash flows from operating activities, excluding acquisition of plant, property and equipment, and including proceeds from sales of plant, property and equipment, as further adjusted to exclude the acquisition of intangible assets and the acquisition of investments, and to include the proceeds from sales and redemption of investments and proceeds from sales of business, net of cash and cash equivalents divested. FY2020 Q3 YTD RESULTS DEMONSTRATE TAKEDA’S CONTINUED RESILIENCE Reported revenue, at JPY 2,427.5 billion (~$23.5B), was impacted primarily by foreign exchange and divestitures, however Takeda delivered year-to-date underlying revenue growth of 1.1% in the third quarter of FY2020, which was driven by strong growth in ENTYVIO, TAKHZYRO, and Immunoglobulin, and was consistent with full year guidance of “low-single-digit growth.” Takeda delivered reported operating profit of JPY 358.7 billion (~$3.5B), which grew 120.7%, reflecting lower purchase price accounting (PPA) and integration costs. Core operating profit, which adjusts for PPA and non-recurring items, declined year-on-year to JPY 780.6 billion (~$7.6B) owing to foreign exchange impact and divestitures. The core operating profit margin was 32.2%. Underlying core operating profit grew 8.5% year-on-year. Underlying core operating profit margin, which adjusts for the impact of foreign exchange and divestiture effects, was 32.1%, driven by synergies and OPEX efficiencies. Takeda’s reported net profit was JPY 178.9 billion, a 320.8% increase compared with the same period in the prior year. Operating cash flow increased by 25.9% to JPY 610.0 billion, strengthening Takeda’s balance sheet and more than enabling the Company to satisfy dividend, debt, and interest payments. Free cash flow, which also reflects capital expenditures and proceeds from asset sales, was JPY 717.5 billion (~$7.0B). This represented a decrease of 3.8% in reported free cash flow versus the prior year; the growth rate was impacted by the ~JPY 375.5BN cash received in July 2019 for XIIDRA ®. Robust cash flow enabled further de-leveraging in Q3 and led to a 3.6x net debt/adjusted EBITDA ratio at the end of the period. The overall impact of the global spread of COVID-19 on Takeda’s consolidated financial results for the nine-month period ended December 31, 2020 was not material, with several offsetting factors. There were adverse effects due to COVID-19 observed in certain therapeutic areas, especially in Neuroscience during periods when stay-at-home restrictions were in place reducing patient visits to medical care providers. This trend has fluctuated throughout the nine-month period, especially in recent months, as transmission of COVID-19 has increased significantly in many parts of the world. These adverse impacts have been partially offset by benefits from prescribing trends during the pandemic, such as an expansion of certain products with a more convenient administration profile that was observed in the early phase of the outbreak. With regard to operating expenses, voluntary suspension of certain business activities such as business travel and events in response to COVID-19 led to lower spending. As a result of these factors, the impact on Takeda’s profit was immaterial. For the latest Takeda communications regarding COVID-19, please click here to visit the COVID-19 Information Center on Takeda’s website. COMMERCIAL UPDATES ACROSS FIVE KEY BUSINESS AREAS Takeda’s five key business areas — Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience — with JPY 1,982.1 billion of reported revenue representing approximately 82% of total Q3 YTD revenues – delivered year-on-year underlying revenue growth of 4.4%. Takeda’s 14 global brands, with reported revenue of JPY 910.3 billion (~$8.8B) in aggregate, delivered a 15.4% increase in Q3 YTD underlying revenue growth compared to a year before. Gastroenterology The Gastroenterology franchise with JPY 588.8 billion in reported revenue represented 24% of sales, with underlying revenue growth of 14%. This was spearheaded by continued exceptional growth through expanded first line share of gut-selective ENTYVIO in the U.S., EU, and Japan. Rare Diseases The Rare Diseases franchise with JPY 446.7 billion in reported revenue represented 18% of sales, with underlying revenue growth declining 3%. The hereditary angioedema portfolio saw 16% underlying revenue growth, driven by continued excellent performance from TAKHZYRO, which continues to expand the hereditary angioedema prophylaxis market. Rare Hematology declined 11% on an underlying basis, with the competitive landscape in line with expectations. Rare Metabolic declined 1% on an underlying basis, but excluding NATPARA the portfolio saw 7% growth. Takeda is working closely with the U.S. Food and Drug Administration (FDA) on a proposed plan to resupply NATPARA in the U.S. and had announced earlier in FY2020 that the required device modifications and product testing will likely delay availability beyond FY2020. PDT Immunology PDT Immunology with JPY 313.0 billion in reported revenue represented 13% of sales, with underlying revenue growth of 9% driven by continued strong Gammagard-Liquid demand in the U.S. and subcutaneous IG worldwide. Albumin sales declined 10% versus prior year, partially due to phasing and supply dynamics in China in 2019 and in some part due to a temporary interruption in submitting batches of Albumin Glass for release in China in Q3, for which we expect a resolution soon. Oncology Oncology with JPY 318.5 billion in reported revenue represented 13% of sales, with underlying revenue growth of 3%. Takeda’s portfolio continues to expand indications as growth brands offset the decline of older products in the portfolio. Neuroscience Neuroscience with JPY 315.1 billion in reported revenue represented 13% of sales, declining 2% on an underlying basis. The portfolio experienced a slowdown in momentum attributable to COVID-19 stay-at-home restrictions that reduced patient visits and diagnoses. A recovery of prescribing trends has been noted, but new patient starts are not yet back to pre-COVID levels. 519.8 -3.6% ENTYVIO +87 yen -3.6% (billion yen) Gastroenterology REPORTED 67.9 PDT Immunology -27 yen +320.8% 420 Year-over-Year UnderlyingRevenue Growth 32.1% +38.1% 333 yen Oncology +8.5% +120.7% NINLARO COST SAVINGS AND DIVESTITURES Synergy deliverables and operational efficiencies supported margin performance, as Takeda delivered a year-to-date underlying core operating profit margin of 32.1%. Takeda is also deleveraging rapidly, with a net debt/adjusted EBITDA ratio of 3.6x at the end of Q3 (December 31, 2020), down from 3.8x in March 2020, even after the full-year dividend payment. Gross debt principal has reduced JPY 1.3TN (~$12.5B) in two years since the quarter ending March 31, 2019 (close of the Shire acquisition was announced on January 8, 2019), and Takeda is on course to meet its medium-term deleveraging goal of 2x within FY2021-FY2023. i Takeda exceeded its $10B non-core asset divestiture target and has announced 11 deals since January 2019 to date for a total aggregate value of up to ~$11.6 billion, most recently including:The completion of the previously announced sale of a portfolio of select OTC and prescription products to Hypera S.A. for a total value of $825 million USD. ( Press Release )The completion of the previously announced sale of TachoSil ® Fibrin Sealant Patch to Corza Health, Inc. for €350 million. ( Press Release )The completion of the previously announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD. ( Press Release )The completion of the previously announced sale of a portfolio of select products to Celltrion Inc. for a total value of $278 million USD inclusive of milestone payments. ( Press Release )An agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. for $322 million USD, subject to customary legal and regulatory closing conditions. ( Press Release ) Takeda further exceeded its original $700 million target and Q2 total of $1.1B for incremental cash from sales of real estate and securities, receiving ~$1.4B to date. As a result, the Company is raising its full year FY2020 Free Cash Flow forecast by JPY 50 billion to JPY 750 – 850 billion. PIPELINE UPDATE: R&D PROGRESS WITH SUBMISSION OF TAK-721, THE FIRST OF SEVEN POTENTIAL FILINGS IN THE NEXT 12 MONTHS Takeda has built a world-class, state of the art R&D engine and has generated a diverse and dynamic pipeline of approximately 40 clinical-stage new molecular entities (NMEs) that is beginning to deliver. The company’s Wave 1 pipeline NMEs, representing potential best-in-class/first-in-class therapies, has a number of notable anticipated near-term late-development milestones, pivotal data readouts or pivotal study starts. Takeda’s pipeline portfolio has the potential to contribute significantly to its growth over the next decade, and remains on track to deliver on its milestone goals. Since Q2, one of its twelve near-term pivotal milestones has already been met (Maribavir phase 3 data readout). This is also one of five pivotal data readouts expected through fiscal year 2022, with additional near-term development milestones expected across all Wave 1 programs. Takeda’s R&D engine continued to advance its Wave 1 pipeline, with recent highlights including:TAK-721 has been granted priority review from the FDA and remains on track to be the first FDA-approved agent to treat eosinophilic esophagitis. TAK-721 previously received both Breakthrough Therapy designation and Orphan Drug designation from the FDA. ( Press Release )TAK-003, Takeda’s tetravalent dengue vaccine candidate, continued to protect against dengue illness with an acceptable safety profile in the two years safety and efficacy follow-up published in The Journal of Infectious Diseases in December 2020. Regulatory submissions to the EMA and dengue endemic countries are expected in FY2020 Q4, containing three years of safety and efficacy follow-up; this data is to be presented at a medical meeting in FY2021.Mobocertinib (TAK-788), a potential new oral standard of care for NSCLC patients with EGFR Exon20 insertion mutations, demonstrated clinically meaningful and durable responses in data presented at the 2020 World Conference on Lung Cancer (WCLC), with a confirmed objective response rate of 35% as assessed by investigator and a median duration of response of 17.5 months. It remains on track for FDA submission in Q4 2020 for Platinum Pretreated Patients with EGFR Exon20 insertion mutations. ( Press release )Maribavir(TAK-620) met its phase 3 primary endpoint for the treatment of transplant recipients with refractory/resistant cytomegalovirus infections ( Press release ). Positive Phase 3 data for TAK-620 will be presented at the Transplantation & Cellular Therapy Meetings (TCT) on February 12 and the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting on March 14-17. Takeda anticipates FDA filing for maribavir as a treatment for CMV infection and disease in transplant patients resistant or refractory to prior therapy in H1 FY2021. Other Notable Updates In 2020, Takeda ranked first in NDA approvals in China, with four approvals including TAKHZYRO ( Press Release ), ENTYVIO, ADCETRIS, and REPLAGAL. At the virtual 62 nd American Society of Hematology (ASH) Annual Meeting & Exposition in December 2020, Takeda presented nine abstracts on key learnings from real-world data and retrospective studies. Takeda continues to gather and apply real-world evidence in the treatment of hemophilia, von Willebrand disease (VWD) and sickle cell disease (SCD) and advance personalized treatment in its ongoing commitment to people living with bleeding disorders. ( Press Release ) At the 2020 American College of Allergy, Asthma and Immunology (ACAAI) Virtual Annual Scientific Meeting, Takeda shared final results from the Phase 3 HELP Study™ Open-Label Extension that demonstrate TAKHZYRO (lanadelumab-flyo) injection as a potential long-term preventive treatment option in patients with Hereditary Angioedema. The results were also published in the November 2020 issue of ACAAI’s journal Annals of Allergy, Asthma & Immunology. ( Press Release ) Lastly, Takeda is excited about the recent regulatory progress of a number of transformative therapies, including the FDA approval for the Supplemental New Drug Application (sNDA) of ICLUSIG (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML. ( Press Release ) KEY CORPORATE INITIATIVES Several examples of corporate achievements in Q3 demonstrate Takeda’s progress toward its vision — “discover and deliver life-transforming treatments, guided by our commitment to Patients, our People and the Planet.” Patients: Takeda Demonstrates Industry Leadership in 2021 Access to Medicines Index Takeda was ranked sixth overall in the 2021 Access to Medicine (AtM) Index. A rigorous, biennial research project, the AtM Index combines data-collection, verification, scoring and analysis to compare 20 of the world’s largest pharmaceutical companies on their efforts to address access to medicines. The company achieved notable high scores in all three technical areas evaluated by the Index, including being ranked first in “Governance of Access”. Takeda also demonstrated strong performance in the areas of health strengthening and compliance. This ranking demonstrates Takeda’s values-driven strategy and how an ‘Access First’ approach across its Growth & Emerging Markets region is helping patients overcome access challenges in a more sustainable manner. ( Press Release ) People: Takeda Receives Global Top Employer Recognition Takeda was one of only 16 companies to be named as a global Top Employer ® for 2021, an accolade the company has now received for a fourth consecutive year. The Top Employers Institute provides annual award certification to companies with outstanding culture, work environments, benefits and opportunities for their people based on the results of its HR Best Practices Survey. Takeda excelled globally in the areas of Values, Ethics & Integrity, Organizational Change, Leadership, Sustainability, Performance Management and Engagement and was also certified as a Top Employer in four regions and 38 countries. This honor demonstrates Takeda’s continued commitment to creating an exceptional people experience for its global workforce. ( Press Release ) Planet: Takeda Achieves Carbon Neutral Goal Takeda recently announced it achieved carbon neutrality in its value chain for its fiscal year 2019. This milestone was met by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. Such actions collectively address 100 percent of Takeda’s fiscal year 2019 scope 1, 2 and 3 emissions and represent a significant step forward in Takeda’s sustainability journey. Minimizing the environmental impact of its business is a critical priority for Takeda and at the heart of its purpose: achieving Better Health for People, Brighter Future for the World. ( Press Release ) Read more about how Takeda continues to deliver on its commitments to patients, people and the planet through its purpose-led sustainability commitment in its 2020 Sustainable Value Report: https://www.takeda.com/corporate-responsibility/sustainable-value-report/ COVID-19 UPDATE Guided by its values, Takeda’s response to COVID-19 has focused on protecting the health and safety of employees, striving to ensure its medicines are available to patients who rely on them and playing a part to reduce transmission and support the communities where its employees live and work. Takeda has also undertaken a number of efforts to help the world respond to COVID-19, most recently including: +0.7pp FY2020 UPDATED FORECAST (February 2021) +13.7% Facebook 717.5 Business areas 180 Low-teen growth +1.1% 115 yen UNDERLYING (2) (Non-IFRS) (1) Q3 YTD Global Brand Highlights 3,200.0 79 Operating Cash Flow Core EPS (Yen) 700-800 Takeda has solid growth momentum heading into Q4 FY2020 and potential for accelerated underlying growth and achieving an underlying core operating profit margin in the mid-30s over the medium term. Core and underlying guidance for FY2020 remains unchanged. Key Assumptions in FY2020 Forecast Company guidance reflects management’s expectations for continued business momentum across Takeda’s five key business areas, underlying revenue growth of its 14 global brands, and accelerated realization of cost synergies. FY2020 guidance also reflects the following key assumptions, including (i) that there will not be an additional 505(b)2 competitor for subcutaneous VELCADE launched in the U.S. within FY2020; (ii) includes the impact of divestitures disclosed by Takeda as through February 4, 2021, with the exception of the divestment of Takeda Consumer Healthcare Company and non-core assets in China; and (iii) management’s current expectations regarding COVID-19. Based on currently available information, Takeda believes that its financial results for FY2020 will not be materially affected by COVID-19 and, accordingly, Takeda’s FY2020 forecast reflects this belief. However, the situation surrounding COVID-19 remains highly fluid, and future COVID-19-related developments in FY2020, including new or additional COVID-19 outbreaks and additional or extended lockdowns, shelter-in-place orders or other government action in major markets, could result in further or more serious disruptions to Takeda’s business, such as slowdowns in demand for Takeda’s products, supply chain related issues or significant delays in its clinical trial programs. These events, if they occur, could result in additional impacts on Takeda’s business, results of operations or financial condition, as well as resulting in significant deviations from Takeda’s FY2020 forecast. For more details on Takeda’s Q3 FY2020 results and other financial information, please visit: https://www.takeda.com/investors/reports/quarterly-announcements/ Further Information Takeda will share details regarding its commercial strategy in emerging markets and progress on its pipeline at its upcoming Growth & Emerging Markets Strategic Update call on March 11, 2021 and part 2 of its Wave 1 Pipeline Market Opportunity call on April 6, 2021, respectively. About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited ( TOKYO: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com. Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Certain Non-IFRS Financial Measures This press release and materials distributed in connection with this press release include certain IFRS financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”), such as Underlying Revenue, Core Operating Profit, Underlying Core Operating Profit, Core Net Profit, Underlying Core EPS, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the reconciliation of non-IFRS financial measures to their most directly comparable IFRS measures. Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ Medical information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Financial information Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). The revenue of Shire plc (“Shire”), which was historically, presented by Shire in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), has been conformed to IFRS, without material difference. Convenience translations of JPY figures into USD are included for reference and have been calculated at a rate of JPY/USD of 103.19. During FY2019, Takeda completed the purchase price allocation for the assets acquired and the liabilities assumed as part of the Shire acquisition. Accordingly, PL statements for FY2019 Q3 were retrospectively adjusted. i Please note the December 2020 debt profile assumes completion of ongoing make-whole calls on $1.25B 2021, $0.9B 2021 and $0.3B 2022 (completion scheduled for FY2020 Q4). View source version on businesswire.com:https://www.businesswire.com/news/home/20210203006048/en/ CONTACT: Media Contacts: Japanese Media Kazumi Kobayashi [email protected] +81 (0) 3-3278-2095 Media outside Japan: Holly Campbell [email protected] +1 480-213-8368 Investor Relations: Christopher O’Reilly [email protected] +81 (0) 3-3278-2543 KEYWORD: JAPAN ASIA PACIFIC INDUSTRY KEYWORD: ONCOLOGY HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Takeda Pharmaceutical Company Limited Copyright Business Wire 2021. PUB: 02/04/2021 01:00 AM/DISC: 02/04/2021 01:01 AM http://www.businesswire.com/news/home/20210203006048/en 248.0 Twitter EPS (JPY) TAGS Facebook Reported Operating Profit Core Operating Profit Margin Low-30s% Reported Net Profit Core Operating Profit Free Cash Flow 780.6 (3) ( Press Release ), ( Press Release ) Takeda licensed TAK-919 (Moderna) and TAK-019 (Novavax) COVID-19 vaccines in Japan, with approvals expected in FY2021 Reported EPS (Yen) 65.9 420 Q3 FY2020 YTD Margin Rare Diseases ALUNBRIG 358.7 180 +25.9% 30.8% Annual Dividend per Share (Yen) Pinterest Press Release Pinterest (billion yen, exceptpercentages and pershare amounts) Previous articleXiaomi’s Latest Air Charging and G9 Vacuum Cleaner DebutNext articleGlobal Residential Air Purifier Market 2020-2024: Market Analysis, Drivers, Restraints, Opportunities, and Threats – Technavio Digital AIM Web Support
Servicers Navigate the Post-Pandemic World 2 days ago in Daily Dose, Featured, Media, Webcasts DS5: Assisting Homeowners in Forbearance The latest episode of DS5: Inside the Industry features a conversation with Courtney Thompson, SVP Default Mortgage, Flagstar Bank.She will discuss the challenges in dealing with the loans in forbearance and what the industry can do to help homeowners avoid foreclosure.You can watch the full video in the embed below or at the following link. Data Provider Black Knight to Acquire Top of Mind 2 days ago Subscribe July 17, 2020 1,388 Views Governmental Measures Target Expanded Access to Affordable Housing 2 days ago Print This Post Servicers Navigate the Post-Pandemic World 2 days ago About Author: Mike Albanese Mike Albanese is a reporter for DS News and MReport. He is a University of Alabama graduate with a degree in journalism and a minor in communications. He has worked for publications—both print and online—covering numerous beats. A Connecticut native, Albanese currently resides in Lewisville. Demand Propels Home Prices Upward 2 days ago 2020-07-17 Mike Albanese Previous: The Week Ahead: Webinar on Homeownership Among Stressed Communities Next: Housing Agency Extends Down Payment Assistance Program Share Save Related Articles Sign up for DS News Daily The Best Markets For Residential Property Investors 2 days ago Governmental Measures Target Expanded Access to Affordable Housing 2 days ago The Week Ahead: Nearing the Forbearance Exit 2 days ago The Best Markets For Residential Property Investors 2 days ago Home / Daily Dose / DS5: Assisting Homeowners in Forbearance Demand Propels Home Prices Upward 2 days ago Data Provider Black Knight to Acquire Top of Mind 2 days ago
Derry’s urban regeneration company Ilex looks set to lose responsibility for one of its two flagship projects in the city.The Department for Social Development has confirmed that it is now considering taking over the project management role for the Fort George former Army base site.The announcement is a blow for Ilex, set up by the Department of Social Development and the Office of the First and Deputy First Minister in 2003 to oversee the regeneration of Derry.Foyle MLA Mark H Durkan says no matter who takes responsility for the the Fort George project, it must benefit the people of Derry…..[podcast]http://www.highlandradio.com/wp-content/uploads/2012/09/markh530.mp3[/podcast] Google+ Pinterest News Twitter Man arrested on suspicion of drugs and criminal property offences in Derry WhatsApp Ilex may lose responsibility for Fort George project in Derry 365 additional cases of Covid-19 in Republic Main Evening News, Sport and Obituaries Tuesday May 25th Pinterest Google+ RELATED ARTICLESMORE FROM AUTHOR Previous articleMan cleared of Michaela McAreavey murder speaks outNext articleMan seriously injured in Letterkenny – Gardai do not suspect assault News Highland Twitter Facebook WhatsApp Gardai continue to investigate Kilmacrennan fire Further drop in people receiving PUP in Donegal Facebook 75 positive cases of Covid confirmed in North By News Highland – September 5, 2012